OneSource is a strong buy due to its robust growth in biologics, successful regulatory approvals, and ambitious FY28 revenue and ROCE targets.
Source Post
The creator discusses OneSource, a specialty pharma CDMO company, highlighting its role in the GLP-1 revolu...
Next Big Thing by AvaniMay 14, 2026
The creator discusses OneSource, a specialty pharma CDMO company, highlighting its role in the GLP-1 revolution. The reel covers recent financial performance, regulatory approvals, and expansion plans, particularly for biologics and semaglutide manufacturing. Despite some expected headwinds in FY26, the company's outlook for FY27-FY28 appears strong with significant revenue and ROCE targets.
Linked Mentions
Tickers discussed in this post
Linked Signals
Tracked calls opened from this post
ONESOURCE.NS
buy opened May 14, 2026
-8.29%